KERENDIA DIN 02564726
Health Canada record
| Active ingredient(s) | FINERENONE 40 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | C03DA05 FINERENONE |
| Original market date | |
| Current status date | 19-Jan-2026 |
| Source | Health Canada DPD |
Establishment licence of the holder
Bayer Inc — licence 101029, currently licensed, last inspection rating C (2023-02-07).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing FINERENONE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02531917 | KERENDIA | BAYER INC | Tablet | FINERENONE 10 MG | Marketed |
| 02531925 | KERENDIA | BAYER INC | Tablet | FINERENONE 20 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 36751 | 2026-01-19 | Supplement to a New Drug Submission (SNDS) | Addition of new indication: KERENDIA (finerenone) is indicated as an adjunct to standard of care in adults with heart failure with left ventricular ejection fraction (LVEF) =40% to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits. Addition of new strength: 40 mg. Update to package labels. |
International API supply for FINERENONE
23 active FDA Drug Master Files.
Request a quote for KERENDIA